pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·1d ago·1 min read
save

Recon: BMS plans $2.3B Houston manufacturing site; MHRA approves Lilly weight-loss drug for weight loss, type 2 diabetes

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

Aug 10, 2026·read at raps ↗

10 Aug 2026 IMDRF details key principles for regulators to adopt PCCPs The International Medical Device Regulators Forum (IMDRF) has finalized a technical document outlining how regulatory agencies may adopt predetermined change control plans (PCCP). The document lists principles for regulators to consider when developing their own PCCP regulations, as well as key elements to include in manufacturers' PCCPs. Regulatory News

source

Reporting by raps.

read at raps ↗
61 words · retrieved 18m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY
drugs
Type 2 Diabetes
topics
Type 2 Diabetes2Obesity

related stories

  • 5d agoLilly climbs, Novo falls as obesity drug battle intensifiesBioPharma Dive
  • 5d ago‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growthFierce Biotech
  • 6d agoNovo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed dataFierce Biotech
  • Jul 23Lilly, with new data, to seek FDA approval of obesity drug retatrutideBioPharma Dive
  • Jul 23Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 dataBioSpace